IP Library Granted Patent US 11,208,413
Granted Patent B2
US 11,208,413 · App. 16/492,292 · Granted Dec 28, 2021

Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Inventors: Peter Hewitt (Craigavon, GB); Frank Burkamp (Craigavon, GB); Andrew Wilkinson (Craigavon, GB); Hugues Miel (Craigavon, GB); Colin O'Dowd (Craigavon, GB)
Assignee: ALMAG DISCOVERY LIMITED
C07D487/04A61K31/519A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,208,413
App. No.
16/492,292
Granted
Dec 28, 2021
Kind
B2
Abstract

The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.

Claims (13)

1. A compound having the formula (I):

or a pharmaceutically acceptable salt or N-oxide derivative thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt or N-oxide derivative thereof, and at least one pharmaceutically acceptable excipient.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt or N-oxide derivative thereof, and at least one pharmaceutically acceptable excipient.

4. The pharmaceutical composition of claim 3 comprising one or more further pharmaceutically active agents.

5. A method of treating cancer in a human or animal patient comprising administering to a patient in need thereof an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the cancer is selected from the group consisting of colorectal, pancreatic, cervical, ovarian, breast, and non-small cell lung cancers.

6. A method of treating cancer in a human or animal patient comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 3 , wherein the cancer is selected from the group consisting of colorectal, pancreatic, cervical, ovarian, breast, and non-small cell lung cancers.

7. The method of claim 5 , wherein the cancer is colorectal cancer.

8. The method of claim 5 , wherein the cancer is non-small cell lung cancer.

9. The method of claim 5 , wherein the cancer is ovarian cancer.

10. The method of claim 6 , wherein the cancer is colorectal cancer.

11. The method of claim 6 , wherein the cancer is non-small cell lung cancer.

12. The method of claim 6 , wherein the cancer is ovarian cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2020
From: HEWITT, PETER; BURKAMP, FRANK; WILKINSON, ANDREW; MIEL, HUGUES; O'DOWD, COLIN
To: ALMAC DISCOVERY LIMITED
Reel/Frame 053719/0381 →
Priority Claims (1)
GB 1703881 · Mar 10, 2017 · national
Continuity (1)
Related Publication 20210128560A1 · May 6, 2021
Cited By (1)
US 12,679,841